Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMEPAN: Timing of start of systemic treatment for asymptomatic metastasized pancreatic cancer
2019-004582-40Phase 3Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of FOLFIRINOX and gemcitabine + paclitaxel in pancreatic cancer (PC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Quality Adjusted Survival. Started Feb 2021; status: active.
02
Drugs
FOLFIRINOXgemcitabine + paclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2019-004582-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004582-40.